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models of rheumatoid arthritis (RA).
Methods: Literature searches were performed on MSC preclinical studies to treat RA. MSC treatment effect sizes
were determined by the most commonly used outcome measures, including paw thickness, clinical score, and
histological score.
Findings: A total of 48 studies and 94 treatment arms were included, among which 42 studies and 79 treatment
arms reported thatMSC improved outcomes. The effect sizes of RA treatments usingMSC, when compared to the
controls, were: paw thickness was ameliorated by 53.6% (95% conﬁdence interval (CI): 26.7%−80.4%), histolog-
ical score was decreased by 44.9% (95% CI: 33.3%−56.6%), and clinical score was decreased by 29.9% (95% CI:
16.7%−43.0%). Speciﬁcally, our results indicated that human umbilical cord derived MSC led to large improve-
ments of the clinical score (−42.1%) and histological score (−51.4%).
Interpretation: To the best of our knowledge, this meta-analysis is to quantitatively answer whether MSC repre-
sent a robust RA treatment in animal models. It suggests that in preclinical studies, MSC have consistently exhib-
ited therapeutic beneﬁts. The ﬁndings demonstrate a need for considering variations in different animal models
and treatment protocols in future studies usingMSC to treat RA in humans to maximise the therapeutic gains in
the era of precision medicine.
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Research in context
Evidence before this study
Rheumatoid arthritis (RA) is a chronic autoimmune disease that
primarily affects the joints. Stem cell therapy, especially mesen-
chymal stromal (or stem) cell (MSC) therapy, is emerging as a po-
tential medical treatment for RA. From animal models to clinical
trials, MSChave shownpromise in the treatment ofmany immune
disorder diseases and have been widely investigated for their ben-
eficial therapeutic effects in rheumatic diseases including RA.
Several preclinical studies have verified the efficacy of MSC in
the treatment of RA, and positive results in clinical trials have
also been reported. We conducted a comprehensive literature
search for articles evaluating the therapeutic potential of MSC in
RA from databases PubMed and Web of Science by June 2019.
The search terms used were (mesenchymal OR mesenchymal
stem cell OR mesenchymal stromal cell OR MSC) AND (rheuma-
toid arthritis OR rheumatoid OR arthritis OR RA), which were suf-
ficiently broad to capture the majority of the published MSC in RA
animal model data. All studies included in this meta-analysis were
done in animal models of RA treated using non-genetically modi-
fied or “native” MSC. Studies with a high risk of any bias were ex-
cluded from the meta-analysis using the SYRCLE's risk of bias
tool. In addition, studies that failed to present sample sizes, stan-
dard deviations, or lacked numerical/graphical results required for
evaluating the effect sizes objectively, were also excluded in the
parametric meta-analysis.
Added value of this study
Thismeta-analysis is a comprehensive and quantitative analysis of
published pre-clinical studies usingMSC to treat RA.Many studies
of MSC treatment of RA animal models have shown case specific
MSC treatment efficacy, but a broader analysis of the field was
necessary to identify which experimental parameters produced
the largest treatment outcomes.We found that therewere consid-
erable efficacy variations, across donor and recipient species,
routes of administration, MSC tissue of origin, timing of MSC in-
troduction, transplant types, dosage of MSC administration and
number of injections. These variables account for significant vari-
ation in treatment outcomes between studies, and should be con-
sidered carefully when designing future pre-clinical and human
clinical trials of MSC to treat RA.
Implications of all the available evidence
This meta-analysis supports the hypothesis that MSC provide
therapeutic benefit with large effect sizes in the RA treatment.
This work is the first meta-analysis article to attempt exploration
of studying heterogeneity from different MSC study designs, in-
cluding different donor species, tissue of origin, injection routes
and dosages of administration. Our analysis could also be used
to inform guidelines (e.g., experimental design, power calculation,
etc.) for the future clinical translation of MSC to the bedside.
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Rheumatoid arthritis (RA) is a chronic autoimmune disease and sys-
temic disorder that primarily affects the joints [1]. In RA, the immune
system attacks the synovial membrane, causing chronic inﬂammation,
disintegration of bone and cartilage, and potential damage to other or-
gans [2,3]. In the United States, it is estimated that about 1.5 millionadults are affected by RA [4]. The conventional treatment regimen is a
progression through corticosteroids, non-steroidal anti-inﬂammatory
drugs (NSAIDs), non-biologic disease-modifying anti-rheumatic drugs
(DMARDs), and biologic DMARDs (e.g., anti-tumour necrosis factor
(anti-TNF) [5,6]. Unfortunately, 15–40% of RA patients become resistant
to long-term treatments and can become non-responsive to all existing
clinical therapies [7,8]. Therefore, there is an exigent need for novel RA
therapies [9,10].
Stem cell therapies are emerging as potential medical treatments
for RA. In particular, mesenchymal stem or stromal cells (MSC) are a
type of multipotent adult stem cells, which are currently used in
many clinical trials. Cells meeting the MSC minimal criteria (per
International Society for Cell Therapy guidelines) [11] have been iso-
lated from bone marrow (BM) [12,13], adipose tissues (AD) [14–16],
umbilical cord (UC) [17–19] and gingival tissue (G) [20,21]. They can
be quickly expanded in vitro and used as an “off-the-shelf” allogeneic
cell therapy due to their immune-evasive properties [22]. From ani-
mal models to clinical trials, MSC have shown promise in the treat-
ment of many diseases including tissue injuries and immune
disorders [22–26]. In particular, MSC have been widely investigated
for their beneﬁcial therapeutic effects in rheumatic diseases [27,28]
including RA, in both preclinical studies [29] and clinical studies
[30–33]. Possible mechanisms of MSC combating RA include MSC-
immune cell contact, induced death of effector lymphocytes and/or
induction of regulatory T (Treg) cells, and production of soluble me-
diators, including anti-inﬂammatory cytokines such as Transforming
growth factors (TGFs) and Indoleamine 2, 3-Dioxygenase (IDO)
[34–36]. Preliminary insight of mechanism of action (MOA) based
on the use of MSC derived from human umbilical cords (hUC-MSC)
in RA treatment in human clinical trials revealed increased levels
of CD4+ CD25+ Foxp3+ Treg cells and decreased levels of pro-
inﬂammatory factors including IL-6 and TNF-alpha in circulation
[30,33].
The purpose of this meta-analysis is to review and analyse preclini-
cal studies of MSC in the treatment of RA. Several variables were com-
pared, including donor species, tissues of origin, routes of
administration, transplant types (i.e., autologous, allogeneic and xeno-
geneic). This meta-analysis also aims to identify optimal treatment var-
iables and conditions bymeta-regression and subgroup analysis, which
can inform future experimental and trial designs. This analysis began by
reviewing each study's quality using an Risk of bias (RoB) tool for ani-
mal intervention studies, presented by the SYstematic Review Centre
for Laboratory Animal Experimentation (SYRCLE): SYRCLE's RoB tool
[37]. Next, the effect size of MSC treatmentwas determined for the clin-
ical score, paw thickness and histological scores. Finally, the MSC efﬁ-
cacy was examined across several variables of interest including
dosage, number of injections, tissue source of MSC, MSC donor species,
and other parameters listed in Tables 1 and 2.
2. Materials and methods
Literature search and inclusion criteria. (See Supplementary
materials.)
Data extraction. (See Supplementary materials.)
Evaluating the risk of bias. (See Supplementary materials.)
2.1. Effect size estimation
The effect sizes ofMSC therapywere analysed based on the three dif-
ferent indicators most frequently used in preclinical MSC in RA animal
studies: [1] clinical score (a semi-quantitatively summative macro-
scopic measure of animal anatomical conditions), [2] histological score
(a pathological microscopic measure of joint conditions), and [3] paw
thickness (ameasurement of paw swelling to determine arthritis sever-
ity) [38]. Due to methodical variations in histology scoring, we sepa-
rated histological data into a “general” score if the paper combined
565L. Liu et al. / EBioMedicine 47 (2019) 563–577several scoring parameters into an overall score. In papers that listed
individual histology assessment parameters (bone erosion, cartilage
damage, and inﬂammation) we reported them individually. We aver-
aged (presented as mean) both general and individual histological
scores of each treatment arm. The changes in mean clinical scores and
paw thickness were evaluated with the measurements before and
after MSC treatments. If the changes in clinical score and paw thickness
were not provided directly from the included literature, these indicators
were calculated by subtracting themean endpointmeasurement by the
baseline (standard deviations were estimated by assuming all the mea-
surements were independent). All treatment arms included in the
quantitative meta-analysis used PBS as the control group, which is the
most commonly used control, although some high quality studies in-
cluded multiple control groups (e.g. ﬁbroblast and methotrexate). All
study design differences were normalised before comparing the PBS
treated RA group and MSC treatment RA group. Normalisation of data
and effect sizes were determined by the method outlined in Vesterinen
et al. 2013. In brief, the effect sizes were normalised to the sham control
group (i.e. healthy animals) [39]. If therewas no difference between the
MSC treated RA group and the sham control group, it was scored 0. The
directionality was positive if indicating more pathological conditions,
therefore a higher score means worse disease conditions. Thus, positive
efﬁcacy fromMSC treated RA group shows a negative normalised value.
The effect sizes were estimated by subtracting the normalised values of
the MSC treated RA group by the PBS treated RA group. All the effect
sizes are unitless due to normalisation (Eq. 1). Some studies included
multiple treatment arms, so to avoid overestimating treatment effects
and unit-of-analysis error, we split the PBS treated RA group so that it
could be compared to each treatment arm separately, without being
counted more than once. If there were not enough PBS-treated RA
mice to split, the MSC treated groups were combined. Standardised
mean difference (SMD) using exact Hedge's G effect sizes was also per-
formed as sensitivity analysis.
ESi ¼ 100%
 xc−xshamð Þ− xrx−xshamð Þ
xc−xshamð Þ
 directionx ¼−b
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
b2−4ac
p
2a
ð1Þ
2.2. Statistical analysis, subgroup analysis and meta-regression
The random-effectsmodelmethod in the R package “meta”was used
to calculate the mean effect size, 95% CIs, forest plots, and signiﬁcance.
Heterogeneity was calculated/analysed in the restricted maximum-
likelihood estimator (REML) with the Ι2 and τ2 values, which are the
ratio of true heterogeneity to total observed variation and the variance
between studies respectively. A subgroup analysis was conducted
using routes of administration, donor species, transplant types, or tissue
of origin of MSC as categorical variables assuming there is a common τ2
among the groups. A mixed-effects model of regression was performed
in the “metafor” package in R to address heterogeneity. Variations in
MSC tissues of origin, MSC donor species, routes of administration, dos-
age of administration, number of injections and transplant types were
tested as covariate separately. After ﬁtting moderators, residual hetero-
geneity was assessed by the “adjusted R2 value”, which can be used to
test variation in the effect size. Potential interactions between the
moderators were also tested. An omnibus test, as well as all pairwise
comparisons between the factor levels, were used for the statistical
test of the moderator, and a likelihood ratio test (LRT) was used to
test the interaction. The conﬁdence intervals were adjusted with the
Knapp-Hartung method. The p-value threshold was set to 0.1 for het-
erogeneity, to increase the power of the test, and 0.05 for other tests.
Funnel plots were drawn with the meta package to assess the publica-
tion bias, if there were at least nine included studies in that indicator.Trim and ﬁll correction were done where there was signiﬁcant
asymmetry of the plot.
3. Results
3.1. Study characteristics
The article selection process is summarised in Fig. S1 (See Supple-
mentary Materials). Literature searches retrieved 4745 articles from
PubMed and the Institute for Scientiﬁc Information Web of Science, in
which 661 were duplicates. A total of 3912 articles were excluded by
title alone. Overall, articleswere screened by title and abstract, however,
a further 111 did not meet the inclusion criteria. The remaining 61 full
text articles were assessed for eligibility resulting in 48 articles meeting
the criteria to be included in the meta-analysis review (Table 1).
A total of 48 studies and 94 treatment arms were identiﬁed
(Table 1), which were further categorised based on experimental vari-
ables of interest listed in Table 2. In this meta-analysis, 86.2% of the
treatment arms used mouse models, and 13.8% of the treatment arms
used rat models. The RA models included mainly collagen-induced
arthritis (CIA) induction (83.0%) and adjuvant-induced arthritis (AIA)
induction (11.7%). Among 94 treatment arms, 72.3% used an
immunisation booster for model induction. Human derived MSC were
used in 52.1% of the 94 treatment arms, 37.2% used murine MSC, and
8.5% used rat derived MSC. The tissue of origin of MSC varied by study,
such that 13.8% of 94 treatment arms used umbilical cord, 42.6% bone
marrow, and 14.9% adipose. OtherMSC tissue of origin including gingiva
was used in 28.7% of the treatment arms. Transplant types were also
compared, such that 55.3% of the 94 treatment arms were xenogeneic,
24.5% allogeneic, and 20.2% autologous. The routes of administration
were intravenous (IV) injection in 57.4% of 94 treatment arms, 26.6% in-
traperitoneal (IP) injection and 9.6% intra-articular (IA) injection
(Tables 1 and 2).
3.2. Quality of included studies
The quality of studies was assessed (Fig. S2, Supplementary mate-
rials). Most studies avoided selection/reporting bias, and all reported
the baseline characteristics (Q2). Selective outcome (Q9) and other
sources of bias (Q10) appeared to be low in these reports. Nonetheless,
few studies attempted to report the strategies to mitigate potential
performance bias, detection bias and attrition bias. Therefore, there
was uncertainty regarding the actual risk of bias. Notably, some of the
studies included blindness on evaluation protocol (Q7: 35.42% of
“yes”) in their study.
3.3. Effect size
Three indicators were used to study effect sizes in this meta-analysis
review: [1] clinical score, [2] histological score, and [3] paw thickness.
Qualitative analysis was done to show the effect size ofMSC administra-
tion in preclinical studies of RA (Table 2). MSC improved outcomes (i.e.,
at least one indicator was improved) in 87.5% of the 48 studies and in
84.0% of the 94 treatment arms (Tables 1 and 2). Clinical score differ-
ence was used to illustrate effect size for MSC administration in 73.4%
of the 94 treatment arms, 38.3% included histological scoring and
39.4% included paw thickness difference. In terms of clinical score,
87.0% of 69 treatment arms favoured MSC treatment, while 13.0%
favoured the PBS control treatment. Histological scoring showed 91.7%
of the 36 total treatment arms favoured MSC treatment, vs 8.3% for
PBS control. Finally, paw thickness measurements showed 94.6% of
the 37 treatment arms favouredMSC treatment, vs 5.4% for PBS control.
Interestingly, 60.0% of the treatment arms that favoured PBS control
treatment used MSC derived from mice; however, 98.0% of human
derived MSC improved RA pathophysiology (Table 2).
Table 1
Pre-clinical studies using MSC to treat RA included in this study.
Author (year) Arm P b 0.05 MSC
favour?
Origin Donor Control Transplant
type
Treatment protocol Rcpt Age n
Zhou et al. (2011)S1 1 Y Y AD Human PBS/Other Xenogenic CIA, no booster, IV, Multiple Mouse 8w 10
#Garimella,
et al. (2015)S2
1 Y Y AD Murine PBS Autologous CIA, with booster, IP, Single Mouse 8-10w 6–7
Chen et al. (2013)S3 1 Y Y Other (G) Human Nil Xenogenic CIA, IV, Single Mouse 8-10w 6
2 Y Y Other (G) Human Nil Xenogenic CIA, IV, Single Mouse 8-10w 6
3 Y Y Other (G) Human Nil Xenogenic CIA, IV, Single Mouse 8-10w 6
Lee et al. (2015)S4 1 Y Y BM Other PBS Xenogenic CIA, with booster, IP, Multiple Mouse 7-9w 5
2 Y Y Other
(SF)
Other PBS Xenogenic CIA, with booster, IP, Multiple Mouse 7-9w 5
Augello et al. (2007)S5 1 N Y BM Murine PBS Allogeneic CIA, with booster, IP, Multiple Mouse 6w 6
#Chen et al. (2009)S6 1 Y N BM Murine Nil Autologous CIA, with booster, IV, Single Mouse 8-10w N/A
Lopez-Santalla,et al. (2015)S7 1 Y Y AD Human Other Xenogenic CIA, with booster, IV, Single Mouse 8w 64
#Greish et al.
(2012)S8
1 Y Y UC Human PBS/Other Xenogenic AIA, no booster, IA, Single Rat N/A 8
Gonzalo-Gil,
et al. (2016)S9
1 Y Y Other (ESC) Human PBS Xenogenic CIA, IP, Single Mouse 10w 7
2 Y Y Other (ESC) Human PBS Xenogenic CIA, IP, Multiple Mouse 10w 4
3 Y Y Other (ESC) Human PBS Xenogenic CIA, IP, Multiple Mouse 10w 20
Mao et al. (2010)S10 1 Y Y N/A Rat PBS Xenogenic CIA, with booster, IV, Multiple Mouse 8w 6
#Swart et al. (2016)S11 1 Y Y BM Murine PBS Autologous hPG, IP, Multiple Mouse N/A 10
2 Y Y BM Murine PBS Autologous hPG, IA, Multiple Mouse N/A 10
#Papado-poulou et al. (2012)S12 1 N N BM Rat PBS/Other Allogeneic AIA, IV. Single Rat 7w 4–5
2 N N BM Rat PBS/Other Allogeneic AIA, IV. Multiple Rat 7w 4–5
3 N N BM Rat PBS/Other Allogeneic AIA, IP, Multiple Rat 7w 4–5
4 N N BM Rat PBS/Other Allogeneic AIA, IBM, Multiple Rat 7w 4–5
5 N N BM Rat PBS/Other Allogeneic AIA, IS, Multiple Rat 7w 4–5
6 Y Y BM Murine PBS/Other Allogeneic STA, IP, Multiple Mouse 7w 4–5
Rui et al. (2016)S13 1 Y Y BM Murine PBS Allogeneic CIA, with booster, IV, Multiple Mouse 8-10w 6
2 Y Y Other
(OE)
Murine PBS Allogeneic CIA, with booster, IV, Multiple Mouse 8-10w 6
#Djouad et al.
(2005)S14
1 N Y N/A Murine N/A Allogeneic CIA, with booster, IV, Single Mouse 8-10w 5–11
2 N N N/A Murine N/A Allogeneic CIA, with booster, IV, Single Mouse 8-10w 5–11
3 N Y N/A Murine N/A Allogeneic CIA, with booster, IP, Single Mouse 8-10w 5–11
4 N Y N/A Murine N/A Allogeneic CIA, with booster, IM, Single Mouse 8-10w 5–11
5 N Y N/A Murine N/A Allogeneic CIA, with booster, IA, Single Mouse 8-10w 5–11
Santos et al. (2013)S15 1 N Y UC Human PBS Xenogenic AIA, no booster, IA, Multiple Rat 16w 8
2 N Y UC Human PBS Xenogenic AIA, no booster, IA, Multiple Rat 16w 8
3 Y Y UC Human PBS Xenogenic AIA, no booster, IP, Multiple Rat 16w 8
Wu et al. (2012)S16 1 N Y UC Human PBS Xenogenic CIA, with booster, IA, Single Mouse 7-8w 6
Kim et al. (2014)S17 1 N Y AD Human PBS Xenogenic Curdlan, IP, Multiple Mouse 10-12w 6
Liu et al.
(2010)S18
1 Y Y UC Human PBS/Other Xenogenic CIA, with booster, IP, Multiple Mouse 6-8w 10
Shu et al. (2015)S19 1 Y Y Other (AM) Human Nil/PBS Xenogenic CIA, with booster, IP, Single Rat N/A 6
Park et al. (2016)S20 1 Y Y UC Human Other Xenogenic CIA, with booster, IV, Multiple Mouse 8w 5
2 Y Y BM Human Other Xenogenic CIA, with booster, IV, Multiple Mouse 8w 5
3 Y Y AD Human Other Xenogenic CIA, with booster, IV, Multiple Mouse 8w 5
4 Y Y UC Human Other Xenogenic CIA, with booster, IV, Multiple Mouse 8w 5
5 Y Y BM Human Other Xenogenic CIA, with booster, IV, Multiple Mouse 8w 5
6 Y Y AD Human Other Xenogenic CIA, with booster, IV, Multiple Mouse 8w 5
7 Y Y BM Human Other Xenogenic CIA, with booster, IV, Multiple Mouse 8w 5
8 Y Y BM Human Other Xenogenic CIA, with booster, IV, Multiple Mouse 8w 5
9 Y Y BM Human Other Xenogenic CIA, with booster, IV, Multiple Mouse 8w 5
#Gonzalez et al. (2009)S21 1 Y Y AD Human PBS/Other Xenogenic CIA, with booster, IP, Multiple Mouse 7-10w 8–11
2 Y Y AD Murine PBS/Other Allogeneic CIA, with booster, IP, Multiple Mouse 7-10w 8–10
3 Y Y AD Murine PBS/Other Autologous CIA, with booster, IP, Multiple Mouse 7-10w 8–10
4 Y Y AD Human PBS/Other Xenogenic CIA, with booster, IA, Single Mouse 7-10w 8–11
#Zhao et al. (2015)S22 1 Y Y UC Human PBS/Other Xenogenic CIA, with booster, IV, Single Rat 8w N/A
#Boufﬁ et al. (2010)S23 1 Y Y BM Murine N/A Autologous CIA, with booster, IV, Multiple Mouse 9-10w N/A
2 Y Y BM Murine N/A Allogeneic CIA, with booster, IV, Multiple Mouse 9-10w N/A
3 Y Y BM Murine N/A Autologous CIA, with booster, IV, Multiple Mouse 9-10w N/A
4 Y Y BM Murine N/A Autologous CIA, with booster, IV, Multiple Mouse 9-10w N/A
5 Y Y BM Murine N/A Autologous CIA, with booster, IV, Multiple Mouse 9-10w N/A
6 Y Y BM Murine N/A Autologous CIA, with booster, IV, Multiple Mouse 9-10w N/A
7 Y Y BM Murine N/A Autologous CIA, with booster, IV, Multiple Mouse 9-10w N/A
Sullivan et al. (2012)S24 1 Y N BM Murine PBS Autologous CIA, with booster, IV, Single Mouse 7-9w 12
2 Y N BM Murine PBS Allogeneic CIA, with booster, IV, Single Mouse 7-9w 12
3 Y N BM Murine PBS Allogeneic CIA, with booster, IV, Single Mouse 7-9w 12
Schurgers et al. (2010)S25 1 N N BM Murine PBS Autologous CIA, no booster, IV, Single Mouse 8-12w 9
Liu et al.
(2015)S26
1 Y Y UC Human PBS Xenogenic CIA, with booster, IV, Single Mouse 6-8w 5
Choi et al. (2008)S27 1 N N BM Murine PBS Autologous CIA, with booster, IV, Multiple Mouse 8-12w 10
Park et al.
(2011)S28
1 N N BM Murine PBS Autologous CIA, with booster, IP, Single Mouse N/A 6
Parolini et al. (2014)S29 1 Y Y Other (AM) Human PBS Xenogenic CIA, with booster, IP, Multiple Mouse 8w 8–10
#2 Y Y Other (AM) Murine PBS Allogeneic CIA, with booster, IP, Multiple Mouse 8w 8–10
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Table 1 (continued)
Author (year) Arm P b 0.05 MSC
favour?
Origin Donor Control Transplant
type
Treatment protocol Rcpt Age n
Sullivan et al. (2013)S30 1 N N BM Murine PBS Allogeneic CIA, with booster, IV, Single Mouse 7-9w 10
El-Denshary,
et al. (2013)S31
1 Y Y BM Murine PBS Allogeneic CIA, with booster, IV, Single Mouse 6w 10
Choi et al. (2016)S32 1 Y Y AD Human PBS Xenogenic CIA, with booster, IV, Multiple Mouse 8w 12
#Luz-Crawford,
et al. (2015)S33
1 Y Y BM Murine PBS/Other Allogeneic CIA, with booster, IV, Multiple Mouse 9-10w 16
Kehoe et al. (2014)S34 1 Y Y BM Murine PBS Autologous AIA, IA, Single Mouse 7-8w 6
Gu et al.
(2016)S35
1 Y Y Other (G) Murine PBS Allogeneic CIA, with booster, IV, Single Mouse 6-8w 6
Luo et al. (2019)S36 1 Y Y Other (G) Human Nil Xenogenic CIA, IV, Single Mouse 8-10w 6
2 Y Y Other (G) Human Nil Xenogenic CIA, IV, Single Mouse 8-10w 4
Nam et al. (2018)S37 1 Y Y BM Human Nil Xenogenic CAIA, IP, Multiple Mouse 6w 10
Park et al. (2017)S38 1 Y Y BM Human Nil Xenogenic CIA, IP, Multiple Mouse 6w 5
Shin et al. (2016)S39 1 Y Y Other (UCB) Human Nil Xenogenic CIA, with booster, IP, Multiple Mouse 6-8w 5
2 Y Y Other (UCB) Human Nil Xenogenic CIA, with booster, IV, Single Mouse 6-8w 7
Feng et al. (2018)S40 1 Y Y UC Human PBS Xenogenic CIA, with booster, IV, Single Mouse N/A 5
Zhang et al. (2019)S41 1 Y Y BM Human PBS Xenogenic CIA, with booster, IV, Single Mouse 8w 6
2 Y Y UC Human PBS Xenogenic CIA, with booster, IV, Single Mouse 8w 6
3 Y Y Other (ED) Human PBS Xenogenic CIA, with booster, IV, Single Mouse 8w 6
#Tian et al. (2019)S42 1 Y Y BM Rat PBS Autologous CIA, with booster, IV, Single Rat 3-4w N/A
Abd-Elhalem et al. (2018)S43 1 Y Y BM Rat Nil Autologous AIA, with booster, Transplant Rat 6w 6
Mancheño-Corvo et al. (2017)S44 1 Y Y AD Human Ringer Xenogenic CIA, with booster, IL, Multiple Mouse 8w 34
2 Y Y AD Human Ringer Xenogenic CIA, with booster, IL, Multiple Mouse 8w 34
3 N N AD Human Ringer Xenogenic CIA, with booster, IV, Multiple Mouse 8w 40
Li et al.
(2017)S45
1 Y Y BM Murine Nil Autologous CIA, with booster, IV, Multiple Mouse 7w 5
Yan et al. (2017)S46 1 Y Y SM Human PBS Xenogenic CIA, with booster, IA, Multiple Mouse 7-9w 8
Sun et al. (2017)S47 1 N Y UC Human PBS Xenogenic CIA, with booster, IP, Single Mouse 6-8w 5
Yu et al. (2018)S48 1 Y Y Other (UCB) Human PBS Xenogenic CIA, with booster, IV, Multiple Mouse 6w 5
2 Y Y Other (UCB) Human PBS Xenogenic CIA, with booster, IV, Multiple Mouse 6w 5
3 Y Y Other (UCB) Human PBS Xenogenic CIA, with booster, IV, Multiple Mouse 6w 5
Abbreviations: Age: age of induction, AA: adjuvant-induced arthritis, AD: adipose tissue, AIA: adjuvant-induced arthritis, AM: amniotic membrane, BM: bonemarrow, CAIA: collagen an-
tibody-induced arthritis, CarrIA: carrageenan-induced arthritis, CIA: collagen-induced arthritis, ED: Exfoliated deciduous teeth, ESC: Embryonic stem cells, GI: gingival tissue, hPG: proteo-
glycan-induced arthritis, IA: intra-articular injection, IBM: intra-bone marrow injection, IL: intralymphatic injection, IM: intramuscular injection, IP: intraperitoneal injection, IS:
intrasplenic injection, IV: intravenous injection, Multiple: multiple injections, n: sample size, N/A: not reported, OE: Olfactory ecto, OIA: ovalbumin-induced arthritis, Origin: tissue of or-
igin, PBS: phosphate-buffered saline, Rcpt: recipient specie, Ringer: Ringer's Lactate, SC: subcutaneous injection, SF: Synovialﬂuid, Single: single injection, SM: SynovialMembrane, STA: K/
BxN serum-transfer arthritis, UC: umbilical cord tissue, UCB: umbilical cord blood, w: weeks.
#: studies that have been excluded from the parametric meta-analysis due to missing values or high risk of biases.
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duced by an average of 29.9% compared to the PBS treated RA groups
(Fig. 1). While this reduction was statistically signiﬁcant (p-value
b0.0001), it contained both total and sampling variabilities. The esti-
mated total heterogeneity (τ2) was 0.1524, and Ι2, which is deﬁned as
a ratio of total heterogeneity to total variability, was 96% (p-value
b0.0001) [39]. Second, there was a 44.9% decrease in histological scores
(p-value b0.0001) in MSC treated groups compared to PBS groups in 8
studies (with 9 treatment arms) which used a general histological
score obtained by summarising the pathological condition of the joint
tissues (Fig. 2a). Despite the heterogeneity of this indicator being statis-
tically signiﬁcant (p-value b0.0001), it is much lower than the clinical
score heterogeneity. Some of the studies grouped histology measure-
ments into categories, such as bone erosion, cartilage damage and in-
ﬂammation. For example, 4 studies (5 treatment arms) reported the
histological score for bone erosion, and the normalised mean difference
was −0.538 (p-value = 0.0210) when comparing the MSC treated
groups to the PBS control groups (Fig. S3a, Supplementary Materials).
MSC treatment signiﬁcantly decreased cartilage damage by 51.6% and
reduced inﬂammation by 42.3% (Fig. S3b and S3c, respectively, Supple-
mentary Materials). Third, paw thickness in MSC treatment groups was
signiﬁcantly reduced, on average, by 53.6% (p-value = 0.0017). Varia-
tions between these studies, using paw thickness as an indicator, were
relatively small (τ2 = 0.0792) (Fig. 2b). As a sensitivity analysis, similar
conclusions can be drawn for clinical score and histological score when
using the standardised mean difference (SMD) method (Fig. S4a andS4b, Supplementary Materials). Notably, 88.9% of the 9 included treat-
ment arms showed results favouring MSC treatment in terms of paw
thickness. The wide conﬁdence interval of the SMD estimate of paw
thickness could be due to the high inter-study variability (Fig. S4c, Sup-
plementary Materials).
More thanonemethodwas used in our study to estimate effect sizes.
Systematic results showed that MSC produced a signiﬁcantly beneﬁcial
treatment effect in 42 of the 48 studies and 79 of the 94 treatment arms,
based on the three indicators (paw thickness, clinical score and histo-
logical score). Notably, majority of the meta-analysis results remain ro-
bust in the sensitivity analysis. Over all studies combined (by SMD),
there was a drop (1.383, p-value = 0.0008) in clinical score, a decrease
(1.931, p-value b0.0001) of histological score, and a reduction (2.814, p-
value = 0.0639) of paw thickness (inﬂammation) (Fig. S4, Supplemen-
tary Materials). The non-statistically signiﬁcant decrease of paw thick-
ness by SMD might be due to high inter-study heterogeneity, which is
a result of the presence of high standard deviation in some of the in-
cluded studies [40].
3.4. Subgroup analysis
Clinical scores varied dramatically among the studies, with a τ2 value
of 0.1542. Thus, we performed further analysis by grouping studies ac-
cording to the donor species, tissue of origin, transplant types and ad-
ministration routes of MSC used in treatment (Figs. 3–6). Notably,
human derived MSC demonstrated more consistent and effective
Table 2
Study arms categorised by experimental variables of interest and their qualitative effect
size.
Experimental variables Total no. of arms Favour MSC Favour control
94 79 15
Donor species
Human 49 48 1
Mouse 35 26 9
Rat 8 3 5
Others 2 2 0
Recipient species
Mouse 81 71 10
Rat 13 8 5
MSC transplant types
Autologous 19 14 5
Allogeneic 23 14 9
Xenogenic 52 51 1
MSC tissue of origin
Umbilical cord 13 13 0
Bone marrow 40 27 13
Adipocyte 14 13 1
Others/Unknown 27 26 1
Route of administration
IV 54 43 11
IP 25 23 2
IA 9 9 0
Others 6 4 2
RA model
CIA 78 68 10
AIA 11 6 5
Others 5 5 0
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pared to the overall effect size (Fig. 3). The superior treatment effect of
human derived MSC is statistically signiﬁcant compared to mouse de-
rived counterparts, which is indicated by the non-overlapping conﬁ-
dence intervals between human and mouse MSC groups. Interestingly,
xenogeneic MSC give signiﬁcantly better treatment efﬁcacy in terms of
clinical score than those from other transplant types (Fig. 4). MSC
from different tissue of origin including umbilical cord, gingiva and ad-
ipose showed consistent improvement of clinical score, whereas bone
marrow derived MSC showed a trend of favouring PBS control treat-
ment (Fig. 5). By comparing clinical scores for the donor species and
MSC tissue of origin of the MSC simultaneously, we discovered that
human MSC, especially MSC derived from adipose tissue and umbilical
cord tissue, provided better therapeutic effects, supported by at least
four independent studies (Fig. S5, Supplementary Materials). Notably,
UC-MSC and gingival tissue derived MSC (G-MSC) showed consistent
and robust efﬁcacy as well as the beneﬁcial effect in the subgroup anal-
ysis of general histological score (Fig. S6, Supplementary materials).
When comparing the studies by different administration routes, IP in-
jection gave amore signiﬁcant reduction in clinical score. The decreases
in clinical scores with other administration routes, such as IV injection,
were not signiﬁcant (Fig. 6). Nonetheless, this result might be subject
to other factors. For example, most of studies conducting IV injections
used bone marrow MSC (BM-MSC), with which inconsistent results
were reported among different studies (Fig. 6, Table 1). Speciﬁcally, in
the studies from Sullivan et al., which accounts for most of the IV injec-
tion treatment arms favouring PBS control treatment, the MSC used
have inconsistent cell quality (e.g. low CD73 expression), isolation pro-
tocols and low dosage (1 × 105 cells).
3.5. Meta-regression of effect size
To address the heterogeneity from different variables and investi-
gate the correlation between experimental parameters and effect size,
meta-regression was performed on clinical scores. Predeﬁned potential
moderators were tested. We found that either routes of MSC adminis-
tration or dosage of MSC contributed little heterogeneity, when
analysed separately (Table S2, Supplementary materials). On the otherhand, consistent with the subgrouping results, variation in MSC donor
species accounted for 32.43% (p-value = 0.0006) of the heterogeneity,
whichwas the highest source of variability among tested single moder-
ators (Fig. 3 and Table S2, Supplementary materials). Regression on
transplant types of MSC resulted in a 32.11% reduction in heterogeneity
(p-value = 0.0006) (Table S2, Supplementary materials). Moreover,
adjusting the tissue of origin of theMSC could reduce the total heteroge-
neity by 27.58% (p-value = 0.0315). The interaction between donor
species andMSC tissue of origin was signiﬁcant (p-value= 0.0413), ac-
counting for 43.94% of the heterogeneity (Table S2, Supplementary
materials).
The number of injections administered is another parameter that
should be considered. When the number of injection (categorised into
single or multiple injections) was adjusted separately, the reduction in
heterogeneity was signiﬁcant (p-value = 0.0147) (Table S2, Supple-
mentary materials). Furthermore, there might be interactions between
dosage of MSC and number of injection in the treatment protocol.
When the interaction between dosage and number of injection was
tested, the heterogeneity was decreased by 19.91% (moderator p-
value = 0.0205, interaction p-value = 0.0722) (Table S2, Supplemen-
tary materials). A single injection with ≥2 × 106 cell dosage correlated
with better clinical outcomes (Fig. 7a). However, multiple injections
treatment arms did not show any correlation between cell dosage and
outcomes in clinical score, when a linear regression was used
(Fig. 7b), but if a quadratic regression was used, there was a better out-
come for 2 to 3 × 106 cell dosage (p-value = 0.0391) (Fig. 7c and
Table S3, Supplementary materials). By combining the results above, a
ﬁnal model was built with MSC donor species, MSC tissue of origin,
transplant types, treatment dosage, and number of injections adjusted.
This ﬁnal model explained 58.04% of the heterogeneity (p-value =
0.0017) (Table S2, Supplementary materials).
3.6. Evaluation of publication bias
Funnel plots for clinical score, histological score, and paw thickness
were used to assess the publication bias. There is no signiﬁcant asym-
metry for all the indicators included in this study in which the p-
values of the funnel plot asymmetry for clinical score, histological
score and paw thickness were 0.2060, 0.4007 and 0.9719 respectively
(Fig. 8). Thus, there is no observable publication bias in this meta-
analysis. Multiple studies that reported positive results were out of the
±1.96 standard error boundary in the funnel plot for histological score
(Fig. 8b), so we performed a correction using the trim-and-ﬁll method.
After correction, the symmetry centre shifted to around +0.0545
(Fig. S7b, Supplementary materials). No obvious change could be also
found in the funnel plot for clinical score and paw thickness, after
trim-and-ﬁll (Fig. S7a and S7c, Supplementary materials).
4. Discussion
This meta-analysis examined preclinical studies ofMSC used to treat
RA and supports the hypothesis that MSC provide therapeutic beneﬁt
with large effect sizes. This work is the meta-analysis article to attempt
exploration of study heterogeneity from different MSC study designs,
including different donor species, tissues of origin, injection routes
and dosages of administration [41]. We found that the major contribu-
tor of heterogeneity is donor species of MSC, which accounts for
32.43% of the variations (Table S2, Supplementary materials). Number
of injections, MSC tissue of origin and transplant types also account for
substantial amount of heterogeneity. Notably, when considering MSC
treatment dosage and number of injections together, the variation
decreased by 19.91% (Table S2, Supplementary materials).
This analysis could be used to inform guidelines (e.g., experimental
design, power calculation, etc.) for the future clinical translation of
MSC to the bedside. Even though beneﬁts were signiﬁcant across spe-
cies, delivery routes, time of administration in RA treatment, this
Fig. 1. Forest plots showing the normalised mean difference (MD) and 95% CI of the clinical score for each study included in the meta-analysis. The graph was generated using themeta
package in R. All results have been normalised with sham control group as described in themethods. For all the plots, the vertical line indicates no effect, left hand side indicates favouring
MSC treatment while right side indicates favouring PBS control treatment. The size of the box indicates the weighting of each study, and the thin horizontal whisker indicates the 95% CI.
Random-effects model was used to summarise the effect sizes. Heterogeneity is denoted by the Ι2 and τ2.
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candidates for RA treatment in terms of the efﬁcacy. Our results support
further translational studies of human derived MSC in the treatment of
RA in humans.
The quality of studies and risk of bias were reviewed to investigate
their translational potentials. Sincemost of the published papers related
to MSC-based RA treatment did not include double-blinded studies, the
overall quality of the studies was lowered with increased risk of bias.
Even though most of the studies tried to avoid selection bias and
reporting bias, few studies attempted to report their strategies to miti-
gate the potential performance bias, detection bias or attrition bias.
Therefore, the results from this meta-analysis should be interpreted
with caution. Instead of excluding potentially biased studies from thisreview,we tried to increase the sample size, and therefore the statistical
power, by including more relevant publications. To improve the overall
quality of the studies, we recommend that future studies related to
MSC-based RA treatment should include double-blinded studies in
their protocols.
Intriguingly, from the meta-regression, a single high dosage
(≥2 × 106 cells) is associated with a higher effect size in clinical score
(Fig. 7a). Our results also suggest that multiple injections within a
range of 2 × 106 to 3 × 106 cell dosage per injection lead to an optimal
treatment outcome (Fig. 7c). In clinical studies, it is reported that even
one injection of MSC would be sufﬁcient for therapeutic beneﬁts,
suggesting a singlemoderate dose of MSC treatmentmay lead to RA re-
mission, without the need for frequent, routine administrations [30,31].
Fig. 2. Forest plots showing the normalised mean difference (MD) and 95% CI of (a) histological score, (b) paw thickness for each study included in the meta-analysis. The graphs were
generated using the meta package in R. All results have been normalised with sham control group as described in the methods. For all the plots, the vertical line indicates no effect, left
hand side indicates favouring MSC treatment while right side indicates favouring PBS control treatment. The size of the box indicates the weighting of each study, and the thin
horizontal whisker indicates the 95% CI. Random-effects model was used to summarise the effect sizes. Heterogeneity is denoted by the Ι2 and τ2.
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vious clinical studies [30–33]. For further studies, especially for early
phase clinical trials, exploration of the optimal dosage range (i.e., the
range of dosage that could exert pharmacological effects without signif-
icant toxicity) of MSC treatments is needed because few studies have
been done on the dose-response relationship of MSC therapy in RA.
Human derivedMSCwere used in 49 of the total 94 treatment arms,
and almost all of them showed therapeutic beneﬁts (Figs. 3–6, and
Table 2). Mouse derived MSC showed therapeutic beneﬁts in 74.3% of
the 35 treatment arms, and majority of the studies that favoured PBS
control treatment were from mouse derived MSC (9 effects in 35 treat-
ment arms), which suggests that human derived MSCmay present bet-
ter therapeutic effects compared to those from mice, in animal RA
models. This observation could be related to the fact that humanderived
MSCwere of xenogeneic implantation in the animalmodels of RA. These
ﬁndings also implicate that autologous or donor recipientHLAmatching
MSC may not be necessary for more effective therapeutic outcomes inhuman RA treatment. In fact, this ﬁnding suggests that an appropriate
level of immune incompatibility between donor cells and the host
may be beneﬁcial for cell therapy in some context.
We also investigated the effects of different MSC tissue of origin
(Table 2 and Fig. 5) and found that UC-MSC (13 out of 13 reported
positive effects; all human derived), AD-MSC (13 out of 14 reported
positive effects) and G-MSC (5 out of 5 reported positive effects) have
shown better RA treatment, compared to other tissue of origin, such
as BM-MSC (27 out of 40 reported positive effects, whereas 13 treat-
ment arms reportingnegative therapeutic effects). Therewere no statis-
tically signiﬁcant differences between UC-MSC, AD-MSC and G-MSC
clinical scores found in this study. However, UC-MSC and G-MSC
showed better treatment outcomes in regard to histological scores.
Additionally, autoantibody levels are considered as an important
parameter regardingMSC treatments in RA [21,42]. Our results showed
that MSC signiﬁcantly decreased the serum levels of anti-collagen II
(IgG) antibodies (Figs. S8, S9 and Table S1, Supplementary materials).
Fig. 3. Forest plots showing normalisedmean difference (MD) of clinical score changes and 95% CI for the subgroup ofMSCdonor species. The graphwas generated using themeta package
in R. All results were normalised with the sham control group as described in the methods. For all the plots, the vertical line indicates no effect, left hand side indicates favouring MSC
treatment while right side indicates favouring PBS control treatment. The size of the box indicates the weighting of each study, and the thin horizontal whisker indicates the 95% CI.
Random-effects model was used to summarise the effect sizes. Heterogeneity is denoted by the Ι2 and τ2.
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stem cells should take into account the inherent problems with having
heterogeneity between studies. It would improve the reliability of
data coming from these studies if they attempted to minimise variationof comparable data, such as the animal models being used, themethods
for evaluating disease levels, the number of experimental groups evalu-
ated in a single study, and the methods used to prepare cells. Other
variables such as the stem cell's species and tissue origin, timing of
Fig. 4. Forest plots showing normalisedmean difference (MD) of clinical score changes and 95% CI for the subgroup of transplant types. The graphwas generated using themetapackage in
R. All results were normalised with the sham control group as described in the methods. For all the plots, the vertical line indicates no effect, left hand side indicates favouring MSC
treatment while right side indicates favouring PBS control treatment. The size of the box indicates the weighting of each study, and the thin horizontal whisker indicates the 95% CI.
Random-effects model was used to summarise the effect sizes. Heterogeneity is denoted by the Ι2 and τ2.
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optimised to the parameters that have been previously provenmost ef-
ﬁcacious, unless further data is provided as to why these optimalmethods were not used. In certain cases, one of these parameters may
be better than others, but until more studies try to minimise heteroge-
neity of other parameters, the relative merits of each study will not be
Fig. 5. Forest plots showingnormalisedmean difference (MD) of clinical score changes and95%CI for the subgroupMSC tissue of origin. The graphwas generatedusing themeta package in
R. All results were normalised with the sham control group as described in the methods. For all the plots, the vertical line indicates no effect, left hand side indicates favouring MSC
treatment while right side indicates favouring PBS control treatment. The size of the box indicates the weighting of each study, and the thin horizontal whisker indicates the 95% CI.
Random-effects model was used to summarise the effect sizes. Heterogeneity is denoted by the Ι2 and τ2. Mixed* indicates the treatment arm contains more than one type of MSC
tissue of origin.
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Fig. 6. Forest plots showing normalised mean difference (MD) of clinical score changes and 95% CI for the subgroup of routes of administration. The graph was generated using themeta
package in R. All results were normalised with the sham control group as described in themethods. For all the plots, the vertical line indicates no effect, left hand side indicates favouring
MSC treatment while right side indicates favouring PBS control treatment. The size of the box indicates the weighting of each study, and the thin horizontal whisker indicates the 95% CI.
Random-effects model was used to summarise the effect sizes. Heterogeneity is denoted by the Ι2 and τ2.
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Fig. 7. Regression model with regression line is shown in (a) single MSC injection
treatment, (b) multiple MSC injections treatment (linear regression), and (c) multiple
MSC injections treatment (quadratic regression). The size of the dot is proportional to
number of injections. The dashed lines in (a, b, and c) represent the 95% CIs. The red line
represents the trend of interactions between dosage of MSC and normalised difference
in clinical score changes. The size of the dot is proportional to the weighting given to the
study and the detailed weighting of each study could be found in Fig. 1.
Fig. 8. Funnel plot for (a) clinical score, (b) histological score, and (c) paw thickness. The funn
difference), or a model after regression (horizontal axis is the residual value). Each dot in the
the study results.
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eters and minimise heterogeneity in future studies. Finally, when the
ﬁeld further progresses in human RA clinical trials of MSC, patient/dis-
ease heterogeneity and disease stages are among the most critical
variables that can affect MSC's therapeutic efﬁcacy. Note that the conse-
quences and implications of these analyses may be restricted to animal
models of arthritis and could not be directly extrapolated to rheumatoid
arthritis in humans. The differences in the models versus human dis-
eases and the fact that most studies are xenogeneic make the relevance
to human disease debatable. In the era of precision medicine, therefore,
correlations between patient/disease characteristics (e.g. based on
genetic analyses and biomarkers), clinical outcomes, MSC characteris-
tics as well as preclinical animal data will be critical to deﬁne MSC
mechanism of actions and identify MSC products for given patient
subpopulations.
RA is a debilitating chronic disorder that affects 1.3 million
Americans. The current treatments, including NSAIDs, conventional
synthetic DMARDs, and biologic DMARDs [43], do not restore immune
balance and are associated with side effects. Importantly, 30–40%
patients are refractory to current treatments [9,44]. Accumulating clini-
cal evidence (Table S4, Supplementary Materials) has demonstrated
that MSC (including AD, BM, UC, or UC blood derived) are potent in
modulating the immune system and improving RA symptoms through
production of trophic and anti-inﬂammatory factors, and the induction
of self-tolerance [30–33,45–47]. For example, pioneering studies testing
hUC-MSC products have been conducted, in several indications includ-
ing RA. Results of two clinical studies, one in adult refractory RA patients
(n = 172) and the other in refractory juvenile idiopathic arthritis (JIA)
patients (n = 10), have demonstrated the safety and preliminary efﬁ-
cacy of hUC-MSC products in RA treatment [30,33].
Both animal and human clinical studies have demonstrated that
MSC could modulate the immune system and decrease RA symptoms
[30,34,35]. These studies indicate that the alleviation of disease symp-
toms are probably caused by the innate ability of MSC to dampen the
immune response and induce tolerance [34]. For instance, transplanta-
tion of hUC-MSC into RA patients led to a signiﬁcant increase in CD4+
CD25+ Foxp3+ Treg cells, a decrease in IL-6 and TNF-alpha, and induc-
tion of disease remission [30]. Further analysis on variables, including
Treg cells levels, and pro−/anti-inﬂammatory factors,will be performed
to evaluate the treatment effects from MSC on RA. Several factors from
preclinical and clinical ﬁndings support the conclusion that MSC ther-
apy can be a safe and effective treatment for patients who are refractory
to current RA therapies [31,32]. The role and inﬂuence of MSC on pro-
moting or inhibiting existing tumour development are controversial
[48]. Due to mixed results of MSC on tumour relapse [49,50], toxicology
studies including tumorigenicity would be recommended before MSCel plots used either a model without regression (horizontal axis is the normalised mean
ﬁgure represents a study, with the y-axis signifying study quality and the x-axis showing
576 L. Liu et al. / EBioMedicine 47 (2019) 563–577administration to patients and caution should be taken for patientswith
existingmalignancy due to the unknown effect ofMSCon tumours.MSC
have an overall positive safety record in hundreds of clinical trials across
many different disease indications [51]. All in all, this review suggests
MSC therapy have a high potential to become a valuable treatment
option for human RA disease.
5. Conclusions
To the best of our knowledge, this meta-analysis is to quantita-
tively answer whether MSC represent a robust RA treatment option
in animal models. It suggests that in preclinical studies in RA animal
models, MSC have consistently exhibited therapeutic beneﬁts based
on clinical scores, histological scores and paw thickness. These ﬁnd-
ings were also robust after correction of publication bias. We also
found that there were considerable efﬁcacy variations, across donor
and recipient species, routes of administration, MSC tissue of origin,
timing of MSC introduction, transplant types, dosage of MSC admin-
istration and number of injections. These ﬁndings demonstrate the
need for considering variations in different animal models and treat-
ment protocols in future studies using MSC to treat RA in humans, in
order to maximise the therapeutic gains in the era of precision
medicine.
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